Update on toxicology study for SDC-1801

AI SummaryClose X

Sareum Holdings PLC has discontinued its 16-week GLP preclinical toxicology study for SDC-1801 after unexpected safety findings emerged. The issues disproportionately affected the control group, which received an inactive dosing solution, suggesting the findings are unlikely related to SDC-1801. Dosing has been terminated, and the study will be formally closed after scheduled analyses. Sareum is reviewing data with experts to determine the cause and next steps and is in discussions with alternative providers to restart the study as soon as possible. The company anticipates completing the full toxicology study with its existing cash resources, despite this setback.

Disclaimer*

UK 100

Latest directors dealings